IGF2 and cancer: On the other hand, treatment of cancer cells with the anti-IGF-IR mAb cixutumumab paradoxically triggers cancer cells to produce IGF2, which in turn recruits macrophages and fibroblasts to promote angiogenesis and metastasis thereby hampering the efficacy of cixutumumab [190].